Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model

Molecular Neurobiology

Volumn 49, Issue 3, 2014, Pages 1282-1292

  Chotibut, Tanya ^a   Davis, Richard W ^a   Arnold, Jennifer C ^a   Frenchek, Zachary ^a   Gurwara, Shawn ^a   Bondada, Vimala ^b   Geddes, James W ^b   Salvatore, Michael F ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

6 OHDA; Ceftriaxone; GLT 1; Neuroprotection; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

AMPHETAMINE; CEFTRIAXONE; EXCITATORY AMINO ACID TRANSPORTER; GLUTAMIC ACID; OXIDOPAMINE; SERINE; SODIUM GLUCOSE COTRANSPORTER 1; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG MECHANISM; LOCOMOTION; MALE; MEDIAL FOREBRAIN BUNDLE; MOTOR DYSFUNCTION; NEUROPROTECTION; NEUROTRANSMITTER UPTAKE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PROTEIN PHOSPHORYLATION; RAT; RAT MODEL; SUSCEPTIBLE POPULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; PARKINSON DISEASE, SECONDARY; SPRAGUE DAWLEY RAT; TOXICITY;

ANIMALS; CEFTRIAXONE; CORPUS STRIATUM; GLUTAMIC ACID; MALE; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; TYROSINE 3-MONOOXYGENASE;

EID: 84902546439     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8598-0     Document Type: Article

References (87)

1. Fonnum F (1984) Glutamate: a neurotransmitter in the mammalian brain. J Neurochem 42:1-11
2. Behrens PF, Franz P, Woodman B, Lindenberg KS, Landwehrmeyer GB (2002) Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 125:1908-1922
3. Lievens JC, Salin P, Nieoullon A, Kerkerian-Le Goff L (2001) Nigrostriatal denervation does not affect glutamate transporter mRNA expression but subsequent levodopa treatment selectively increases GLT1 mRNA and protein expression in the rat striatum. J Neurochem 79:893-902 (Pubitemid 33086527)
4. Miller BR, Dorner JL, Shou M, Sari Y, Barton SJ, Sengelaub DR et al (2008) Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2mouse. Neuroscience 153:329-337
5. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW (1995) Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38:73-84
6. Kim K, Lee SG, Kegelman TP, Su ZZ, Das SK, Dash R et al (2011) Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol 226:2484-2493
7. Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366-375 (Pubitemid 19238787)
8. Albin RL, Young AB, Penney JB (1995) The functional anatomy of disorders of the basal ganglia. Trends Neurosci 18:63-64
9. Chung EK, Chen LW, Chan YS, Yung KK (2008) Downregulation of glial glutamate transporters after dopamine denervation in the striatum of 6-hydroxydopamine-lesioned rats. J Comp Neurol 511:421-437
10. Hazell AS, Itzhak Y, Liu H, Norenberg MD (1997) 1-Methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP) decreases glutamate uptake in cultured astrocytes. J Neurochem 68:2216-2219 (Pubitemid 27176161)
11. Plaitakis A, Shashidharan (2000) Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease. J Neurol 247(Suppl 2):S1125-S1135
12. Lindefors N, Ungerstedt U (1990) Bilateral regulation of glutamate tissue and extra- cellular levels in caudate-putamen by midbrain dopamine neurons. Neurosci Lett 115:248-252 (Pubitemid 20231622)
13. Meshul CK, Emre N, Nakamura CM, Allen C, Donohue MK, Buckman JF (1999) Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 88:1-16 (Pubitemid 28440387)
14. Robinson S, Freeman P, Moore C, Touchon JC, Krentz L, Meshul CK (2003) Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function. Exp Neurol 180:74-87
15. Touchon JC, Holmer HK, Moore C, McKee BL, Frederickson J, Meshul CK (2005) Apomorphine induced alterations in striatal and substantia nigra pars reticulata glutamate following unilateral loss of striatal dopamine. Exp Neurol 193:131-140 (Pubitemid 40463275)
16. Meredith GE, Totterdell S, Beales M, Meshul CK (2009) Impaired glutamate ho- meostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Exp Neurol 219:334-340
17. Weihmuller FB, Ulas J, Nguyen L, Cotman CW, Marshall JF (1992) Elevated NMDA receptors in parkinsonian striatum. Neuroreport 3:977-980
18. Ulas J, Weihmuller FB, Brunner LC, Joyce JN, Marshall JF, Cotman CW (1994) Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients. J Neurosci 14:6317-6324
19. Sanchez-Pernaute R, Wang JQ, Kuruppu D, Cao L, Tueckmantel W, Kozikowski A et al (2008) Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates. Neuroimage 42:248-251
20. Faden AI, Demediuk P, Panter SS, Vink R (1989) The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 244:789-800
21. Lipton SA, Rosenberg PA (1994) Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330:613-622
22. Choi D (1985) Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci Lett 58:293-297
23. Meldrum B, Garthwaite J (1990) Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 11:379-387 (Pubitemid 20262465)
24. Lau A, Tymianski M (2010) Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 460:525-542
25. Geddes JW, Saatman KE (2010) Targeting individual calpain isoforms for neuroprotection. Exp Neurol 226:6-7
26. Grant RJ, Sellings LH, Crocker SJ, Melloni E, Park DS, Clarke PB (2009) Effects of calpain inhibition on dopaminergic markers and motor function following intrastriatal 6-hydroxydopamine administration in rats. Neuroscience 158:558-569
27. Levesque S, Wilson B, Gregoria V, Thorpe LB, Dallas S, Polikov VS et al (2010) Reactive microgliosis: extracellular micro-calpain and microglia-mediated dopaminergic neurotoxicity. Brain 133:808-821
28. Ambrosi G, Armentero MT, Levandis G, Bramanti P, Nappi G, Blandini F (2010) Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease. Brain Res Bull 82:29-38
29. Armentero MT, Fancellu R, Nappi G, Bramanti P, Blandini F (2006) Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodentmodel of Parkinson's disease. Neurobiol Dis 22:1-9
30. Vernon AC, Zbarsky V, Datla KP, Croucher MJ, Dexter DT (2007) Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J Neurochem 103:1075-1091 (Pubitemid 47568746)
31. Hallert PJ, Standaert DG (2004) Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 102:155-174
32. Nutt JG, Gunzler SA, Kirchhoff T, Hogarth P, Weaver JL, Krams M, Jamerson B, Menniti FS, Landen JW (2008) Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov Disord 15:1860-1866
33. Hubsher G, Haider M, Okun MS (2012) Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 78:1096-1099
34. Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 5:160-170
35. Koller M, Urwyler S (2006) Novel N-methyl-D-aspartate receptor antagonists: a review of compounds patented since 2006. Expert Opin Ther Pat 20:1683-1702
36. Anderson CM, Swanson RA (2000) Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia 32:1-14
37. Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RWet al (1996) Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16:675-686 (Pubitemid 26103145)
38. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K et al (1997) Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276:1699-1702 (Pubitemid 27421977)
39. Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65:1-105
40. Selkirk JV, Nottebaum LM, Vana AM, Verge GM, Mackay KB, Stiefel TH et al (2005) Role of the GLT-1 subtype of glutamate transporter in glutamate homeostasis: the GLT-1-preferring inhibitor WAY-855 produces marginal neurotoxicity in the rat hippocampus. Eur J Neurosci 21:3217-3228 (Pubitemid 40961417)
41. Duan S, Anderson CM, Stein BA, Swanson RA (1999) Glutamate induces rapid upregulation of astrocyte glutamate transport and cell-surface expression of GLAST. J Neurosci 19:10193-10200 (Pubitemid 30228026)
42. Salvatore MF, Davis RW, Arnold JC, Chotibut T (2012) Transient striatal GLT-1 blockade increases EAAC1 expression, glutamate reuptake, and decreases tyrosine hydroxylase phosphorylation at ser19. Exp Neur 234:428-436
43. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE et al (2005) Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433:73-77 (Pubitemid 40101145)
44. van Landeghem FK, Weiss T, Oehmichen M, von Deimling A (2006) Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury. J Neurotrauma 23:1518-1528 (Pubitemid 46489609)
45. Rao VL, Dogan A, Bowen KK et al (2001) Antisense knockdown of the glial glutamate transporter GLT-1 exacerbates hippocampal neuronal damage following traumatic injury to rat brain. Eur J Neurosci 13:119-28 (Pubitemid 32055871)
46. Hirsch EC (2000) Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment. Ann Neurol 47:S115-20
47. Smeyne RJ, Jackson-Lewis V (2005) The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 134:57-66 (Pubitemid 40409495)
48. Leung TC, Lui CN, Chen LW et al (2012) Ceftriaxone ameliorates motor deficits and protects dopaminergic neurons in 6-hydroxydopamine-lesioned rats. ACS Chem Neurosci 3:22-30
49. Sari Y, Prieto A, Barton SJ et al (2010) Ceftriaxone-induced upregulation of cortical and striatal GLT1 in the R6/2 model of Huntington's disease. J Biomed Sci 17:62
50. Brown RH Jr (2005) Amyotrophic lateral sclerosis-a new role for old drugs. N Engl J Med 352:1376-1378
51. Chotibut T, Apple DM, Jefferis R et al (2012) Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake. PLos One. doi:10.1371/journal.pone.0052322
52. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic, Sydney
53. Hudson JL, van Horne CG, Stromberg I, Brock S, Clayton J, Masserano J et al (1993) Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 626:167-174 (Pubitemid 23306825)
54. Salvatore MF, Waymire JC, Haycock JW (2001) Depolarization-stimulated catecholamine biosynthesis: involvement of protein kinases and tyrosine hydroxylase phosphorylation sites in situ. J Neurochem 79:349-360 (Pubitemid 32988951)
55. Salvatore MF, Apparsundaram S, Gerhardt GA (2003) Decreased plasma membrane expression of striatal dopamine transporter in aging. Neurobiol Aging 24:1147-1154 (Pubitemid 37487892)
56. Henn FA, Anderson DJ, Rustad DG (1976) Glial contamination of synaptosomal fractions. Brain Res 101:341-344
57. Suchak SK, Baloyianni NV, Perkinton MS, Williams RJ, Meldrum BS, Rattray M (2003) The 'glial' glutamate transporter, EAAT2 (Glt-1) accounts for high affinity glutamate uptake into adult rodent nerve endings. J Neurochem 84:522-532 (Pubitemid 36182251)
58. Minger SL, Geddes JW, Holtz ML, Craddock SD, Whiteheart SW, Siman RG, Pettigrew LC (1998) Glutamate receptor antagonists inhibit calpain-mediated cytoskeletal proteolysis in focal cerebral ischemia 810:181-199
59. Nickell J, Pomerleau F, Allen J, Gerhardt GA (2005) Age-related changes in the dy- namics of potassium-evoked L-glutamate release in the striatum of Fisher 344 rats. J Neural Transm 112:87-96 (Pubitemid 40104719)
60. Wassum KM, Tolosa VM, Wang J, Walker E, Monbouquette HG, Maidment NT (2008) Silicon wafer-based platinum microelectrode array biosensor for near real- time measurement of glutamate in vivo. Sens Basel Sens 8:5023-5036
61. Salvatore MF, Pruett BS, Dempsey C, Fields V (2012) Comprehensive profiling of dopamine regulation in substantia nigra and ventral tegmental area. J Vis Exp. doi:10.3791/4171
62. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415-455
63. Nakashima A, Mori K, Kaneko YS, Nobuhiro H, Toshiharu N, Ota A (2011) Phosphorylation of the N-terminal portion of tyrosine hydroxylase triggers proteasomal digestion of the enzyme. Bio Biophys Res Com 407:343-347
64. DiFiglia M (1990) Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci 13:286-289
65. Ross CA (2002) Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 35:819-822
66. Andre VM, Cepeda C, Levine MS (2010) Dopamine and glutamate in Huntington's disease: a balancing act. CNS Neurosci Ther 16:163-178
67. Bamford NS, Robinson S, Palmiter RD, Joyce JA, Moore C, Meshul CK (2004) Dopamine modulates release from corticostriatal terminals. J Neurosci 24:9541-9552 (Pubitemid 39441508)
68. David HN, Ansseau M, Abraini JH (2005) Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate-putamen and nucleus accumbens of "intact" animals. Brain Res Rev 50:336-360 (Pubitemid 41654400)
69. Greenamyre JT (1993) Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J Neural Transm Gen Sect 91:255-269
70. Starr MS (1995) Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 19:264-293
71. Yamamoto BK, Davy S (1992) Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J Neurochem 58:1736-1742
72. Greenamyre JT, Hastings TG (2004) Biomedicine. Parkinson's - divergent causes, convergent mechanisms. Science 304:1120-1122 (Pubitemid 38661838)
73. Blandini F, Greenamyre JT, Nappi G (1996) The role of glutamate in the pathophysiology of Parkinson's disease. Funct Neurol 11:3-15 (Pubitemid 26176666)
74. Izumi Y, Yamamoto N, Matsuo T, Wakita S, Takeuchi H, Kume T et al (2009) Vulnerability to glutamate toxicity of dopaminergic neurons is dependent on endogenous dopamine and MAPK activation. J Neurochem 110:745-755
75. Black YD, Xiao D, Pellegrino D, Kachroo A, Brownell AL, Schwarzschild MA (2010) Protective effect of metabotropic glutamate mGluR5 receptor elimination in 6-hydroxydopamine model of Parkinson's disease. Neurosci Lett 486:161-165
76. Schlag BD, Vondrasek JR, Munir M, Kalandadze A, Zelenaia OA, Rothstein JD et al (1998) Regulation of the glial Na+-dependent glutamate transporters by cyclic AMP analogs and neurons. Mol Pharmacol 53:355-369 (Pubitemid 28162855)
77. Tian G, Lai L, Guo H, Lin Y, Butchbach ME, Chang Yet al (2007) Translational control of glial glutamate transporter EAAT2 expression. J Biol Chem 282:1727-1737 (Pubitemid 47076686)
78. Dervan AG, Meshul CK, Beales M, McBean GJ, Moore C, Totterdell S et al (2004) Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease. Exp Neurol 190:145-156 (Pubitemid 39335714)
79. Wang J, Hoekstra JG, Zuo C, Cook TJ, Zhang J (2013) Biomarkers of Parkinson's disease: current status and future perspectives. Drug Discov Today 18:155-162
80. Bevers MB, Neumar RW (2008) Mechanistic role of calpains in postischemic neurodegeneration. J Cereb Blood Flow Metab 28:655-673 (Pubitemid 351432797)
81. Lindgren N, Xu ZQ, Lindskog M, Herrera-Marschitz M, Goiny M, Haycock JW et al (2000) Regulation of tyrosine hydroxylase activity and phosphorylation at ser19 and ser40 via activation of glutamate NMDA receptors in rat striatum. J Neurochem 74:2470-2477 (Pubitemid 30314223)
82. Nafia I, Re DB, Masmejean F, Melon C, Kachidian P, Kerkerian-Le Goff L, Nieoullon A, Had-Aissouni L (2008) Preferential vulnerability of mesencephalic dopamine neurons to glutamate transporter dysfunction. J Neurochem 105:484-496 (Pubitemid 351490014)
83. Maetzler W, Liepelt I, Berg D (2009) Progression of Parkinson's disease in the clinical phase: potential markers. The Lancent Neurology 8:1158-1171
84. Wu Y, Le W, Jankovic J (2011) Preclinical biomarkers of Parkinson disease. Arch Neurol 68:22-30
85. Cenci MA, Lindgren HS (2007) Advances in under standing L-DOPA-induced dyskinesia. Current Opinion in Neurobiology 17(6):665-671
86. Cenci MA, Lundblad M (2006) Post- versus presynap tic plasticity in L-DOPA-induced dyskinesia. Journal of Neurochemistry 99(2):381-392 (Pubitemid 44477196)
87. Chase TN, Oh JD (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends in Neurosciences 23(10 Suppl):S86-S91